Edwards Lifesciences Corporation EW NYSE

Edwards Lifesciences Corporation (EW) has shown moderate revenue growth over the past 3 years, expanding from $5.4B to $6.1B (average +4.6%/yr). Net income reached $1.1B, reflecting exceptional earnings expansion at +38.5%/yr on average. The net profit margin is 17.7%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 78.1% (high), with a -1.8pp trend over the period. With a $45B market cap and MOAT composite score of 76/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (73/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 27-year history, the company was profitable in 25 of 27 years — an excellent long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (76/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 74/100 with 6/7 criteria passed.